SAPREME TECHNOLOGIES B.V.;CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN
发明人:
POSTEL, Ruben,FUCHS, Hendrik
申请号：
EPEP2019/084292
公开号：
WO2020/126627A1
申请日:
2019.12.09
申请国别(地区):
EP
年份:
2020
代理人:
摘要：
The invention relates to a therapeutic combination, comprising a first proteinaceous molecule comprising a first binding site for binding to a first epitope of a first cell-surface molecule, the first proteinaceous molecule provided with at least one saponin covalently bound to an amino-acid residue of said first proteinaceous molecule, and comprising a second pharmaceutical composition comprising a second proteinaceous molecule different from the first proteinaceous molecule, the second proteinaceous molecule comprising a second binding site for binding to a second epitope of a second cell-surface molecule different from the first cell-surface molecule, and comprising an effector moiety, wherein the second epitope is different from the first epitope. An aspect of the invention is a composition comprising the first proteinaceous molecule and the second proteinaceous molecule of the invention. The invention also relates to an antibody-drug conjugate comprising the first proteinaceous molecule of the invention and an effector moiety. An aspect of the invention relates to a pharmaceutical composition comprising the composition or the antibody-drug conjugate of the invention, and optionally further comprising a pharmaceutically acceptable excipient. The invention also relates to the therapeutic combination or the composition or the antibody-drug conjugate or the pharmaceutical composition of the invention, for use as a medicament.The invention also relates to the therapeutic combination of the invention for use in the treatment or prophylaxis of a cancer.L'invention concerne une polythérapie, comprenant une première molécule protéique comprenant un premier site de liaison pour se lier à un premier épitope d'une première molécule de surface cellulaire, la première molécule protéique étant pourvue d'au moins une saponine liée de manière covalente à un résidu d'acide aminé de ladite première molécule protéique, et comprenant une seconde composition pharmaceutique comprenan
